US 12,447,229 B2
Bone implant
Fredrik Ollila, Abo (FI); Nina Lindfors, Grankulla (FI); Robert Bjorkenheim, Helsinki (FI); Gustav Stromberg, Helsinki (FI); Leena Hupa, Abo (FI); Peter Uppstu, Abo (FI); and Jukka Pajarinen, Menlo Park, CA (US)
Assigned to BonAlive Oy, Turku, FL (US)
Appl. No. 16/339,951
Filed by BONALIVE OY, Turku (FI)
PCT Filed Oct. 4, 2017, PCT No. PCT/FI2017/050693
§ 371(c)(1), (2) Date Apr. 5, 2019,
PCT Pub. No. WO2018/065665, PCT Pub. Date Apr. 12, 2018.
Claims priority of application No. 16192500 (EP), filed on Oct. 5, 2016.
Prior Publication US 2020/0038547 A1, Feb. 6, 2020
Int. Cl. A61L 27/10 (2006.01); A61F 2/28 (2006.01); A61L 27/34 (2006.01); A61L 27/54 (2006.01); A61F 2/30 (2006.01)
CPC A61L 27/10 (2013.01) [A61F 2/28 (2013.01); A61L 27/34 (2013.01); A61L 27/54 (2013.01); A61F 2002/2835 (2013.01); A61F 2002/30225 (2013.01); A61F 2002/30322 (2013.01); A61F 2002/30968 (2013.01); A61F 2310/00329 (2013.01); A61L 2430/02 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A bone implant comprising
a porous body comprising particles of bioactive glass comprising a particle size of at least 500 μm, wherein a composition of the particles of bioactive glass comprises 45-59 weight-% of SiO2, 18-25 weight-% of Na2O, 17-25 weight-% of CaO and 0.1-6 weight-% of P2O5, wherein the porous body has an outer surface, and
an external film comprising a thickness of 10 μm-200 μm, made of a biocompatible polymer;
wherein the external film is provided only on a portion of the outer surface and is arranged on the outer surface so as to contact muscle, fascia or periosteum when the bone implant is implanted in a bone;
wherein the biocompatible polymer is selected from a group consisting of polylactide, polyglycolide, poly(lactide-co-glycolide), polycaprolactone, natural collagen polymers and their mixtures with polyethylene glycol; and
wherein the implant induces VEGF expression at at least 8 weeks post implantation.